Is LIMN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Liminatus Pharma (LIMN) rests on Lead anti-CD47 program: IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. The bear case rests on liminatus carries the full stack of risks that define a distressed pre-revenue biotech. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company based in Cerritos, California, focused on therapies that use the immune system to detect and attack cancer cells. Its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody intended as a next-generation immune checkpoint inhibitor, with an initial focus on advanced solid tumors including non-small cell lung cancer. The broader pipeline includes a Guanylyl Cyclase C (GCC) cancer vaccine program and, through its transaction with InnocsAI (governed by an amended definitive merger agreement), CAR-T and antibody candidates such as IBC101, a CD19xCD22 bivalent CAR-T for B-cell malignancies cleared for an early-phase study in Korea, plus a CS1 antibody platform. In August 2026 the company engaged Synex as contract research organization for the Phase 1/2a development of the CD19xCD22 CAR-T. The company has no approved products, generates no revenue, and Yahoo Finance lists a single employee. Liminatus became a public company by merging with the special purpose acquisition company Iris Acquisition Corp and began trading on Nasdaq under the ticker LIMN on May 1, 2024. Since then it has operated under significant financial strain. For 2025 it reported zero revenue and a net loss of roughly $10.2 million, ending the year with only about $338,000 in cash and an accumulated deficit near $38.9 million, prompting management to disclose substantial doubt about its ability to continue as a going concern. A February 2026 equity and warrant financing raised roughly $3.4 million in net proceeds, and over the trailing twelve months to mid-2026 the net loss was about $12.5 million, with roughly $3.0 million of cash and $1.4 million of debt at June 30. On listing status, Nasdaq notified the company in January 2026 that its stock had closed below $1.00 for 30 business days, and in May 2026 it received a delisting determination, which it appealed. The Hearings Panel moved the stock to the Nasdaq Capital Market effective August 4, 2026 and extended the deadline. Stockholders approved a 1-for-50 reverse split, effective after the close on August 20, 2026, which cut the share count from about 67.2 million to about 1.34 million. The stock then closed above $1.00 for 13 straight sessions, and on September 24 Nasdaq told the company the bid-price matter was closed. By October 16, 2026 the shares traded near $3.11, close to their post-split low.
The bull case for LIMN
1. Lead anti-CD47 program.
IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. The company has announced plans to initiate a Phase 1 trial in advanced solid tumors, including non-small cell lung cancer. Positive early safety and signal data would be the main catalyst for the stock. CD47 is a well-studied but historically difficult target where several larger programs have struggled.
2. Pipeline breadth and the InnocsAI deal.
Beyond IBA101, Liminatus has described a Guanylyl Cyclase C cancer vaccine program and, through InnocsAI, CAR-T and antibody candidates, including IBC101, a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. Hiring Synex in August 2026 as the CRO for its Phase 1/2a development is the most concrete clinical step the company has announced this year. A wider pipeline spreads the bet across more shots on goal. It also adds complexity, integration risk, and likely large share issuance to fund and complete the deal.
3. Financing is the immediate driver.
With cash measured in low single-digit millions (about $3.0 million at June 30, 2026), trailing operating cash outflow near $4 million, and a going concern warning, Liminatus depends on continued capital raises to operate. Each raise tends to come at depressed prices and dilutes existing holders, so the timing, size, and terms of the next financing matter more to the share price right now than any clinical readout. With only about 1.34 million shares outstanding after the reverse split, even a small offering can be large relative to the existing float.
4. Nasdaq listing after the reverse split.
The 1-for-50 reverse split did its job on the bid-price rule: the stock closed above $1.00 for 13 consecutive sessions from August 21 to September 9, 2026, and Nasdaq closed the matter on September 24. That removed the most immediate delisting threat. It does not change the business, though, and reverse splits in distressed micro-caps are often followed by further declines; LIMN fell about 11% in the month to October 16 and sits near its 52-week low of about $3.01, so listing standards could come back into focus if the slide continues.
The bear case for LIMN
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit above $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company regained Nasdaq bid-price compliance in September 2026 only through a 1-for-50 reverse split, and continued financings, plus the share issuance tied to the InnocsAI transaction, point to heavy dilution. The stock is a micro-cap worth about $4 million with low liquidity and extreme volatility: on a split-adjusted basis it is down about 90% year to date and about 95% over one year, with a 52-week range of roughly $3.01 to $141.50. A total loss is a realistic outcome.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding LIMN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on LIMN
Too few analysts publish on LIMN for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The LIMN forecast page covers what coverage does exist.
How is LIMN valued? (as of October 2026 (financials through the quarter ended June 30, 2026))
Snapshot for LIMN as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue: $0 (no approved products)
- Net loss (TTM): ~$12.5 million
- Net loss (FY2025): ~$10.2 million
- Cash / debt: ~$3.0 million / ~$1.4 million (Jun 30, 2026)
- Shares outstanding: ~1.34 million after the 1-for-50 reverse split
- Market cap: ~$4 million (share price ~$3.11)
For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the cash burn, and the runway between them. Here the runway is very short: a trailing net loss of about $12.5 million and operating cash outflow near $4 million against roughly $3 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the roughly $4 million market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.
How do you decide if LIMN is a buy?
Rather than asking whether LIMN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold LIMN indirectly through an index or sector ETF before adding more.
What would change your mind on LIMN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Lead anti-CD47 program stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: liminatus carries the full stack of risks that define a distressed pre-revenue biotech fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the LIMN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LIMN against your real portfolio and see your actual exposure before deciding.
Investing in Liminatus Pharma with AI
Connect the broker you already use and ask Walnut's AI how LIMN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is LIMN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Lead anti-CD47 program, with revenue at $0 (no approved products). The bear case rests on liminatus carries the full stack of risks that define a distressed pre-revenue biotech. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell LIMN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.
What is the bull case for LIMN?
+
Lead anti-CD47 program. IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells.
What is the bear case for LIMN?
+
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit above $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company regained Nasdaq bid-price compliance in September 2026 only through a 1-for-50 reverse split, and continued financings, plus the share issuance tied to the InnocsAI transaction, point to heavy dilution. The stock is a micro-cap worth about $4 million with low liquidity and extreme volatility: on a split-adjusted basis it is down about 90% year to date and about 95% over one year, with a 52-week range of roughly $3.01 to $141.50. A total loss is a realistic outcome.
What does Liminatus Pharma do?
+
A distressed, clinical-stage immuno-oncology micro-cap developing the anti-CD47 antibody IBA101 and other cancer immunotherapies, facing going-concern doubt and a Nasdaq delisting appeal.
What would have to change for LIMN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Lead anti-CD47 program) stalling in the reported numbers rather than in the narrative, the risk above (liminatus carries the full stack of risks that define a distressed pre-revenue biotech) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Liminatus Pharma do?
+
Liminatus Pharma is a clinical-stage immuno-oncology company developing therapies that use the immune system to fight cancer. Its lead candidate, IBA101, is a next-generation anti-CD47 monoclonal antibody planned for a Phase 1 trial in advanced solid tumors, and its broader pipeline includes a GCC cancer vaccine and, via InnocsAI, CAR-T programs such as IBC101. It has no approved products and no revenue.
Does LIMN pay a dividend?
+
No. Liminatus Pharma does not pay a dividend. It is a pre-revenue clinical-stage biotech that is burning cash on research and operations and has disclosed going concern doubt, so any available capital goes toward funding the business rather than shareholder payouts. Investors in this kind of company are betting on future clinical progress, not income.
Why did LIMN get a Nasdaq delisting notice?
+
Nasdaq notified Liminatus in January 2026 that its stock had closed below $1.00 for 30 consecutive business days, and in May 2026 it received a formal delisting determination. The company appealed, and the Hearings Panel moved it to the Nasdaq Capital Market on August 4, 2026 with an extended deadline. After a 1-for-50 reverse split on August 20, the stock closed above $1.00 for 13 straight sessions, and on September 24, 2026 Nasdaq said the bid-price matter was closed.
Walnut is informational, not investment advice, and gives no verdict on LIMN. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.